IMV Inc.

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Bristol, VantAI Pair Technologies In Pr

Royalty financings were relatively few and far between in the first quarter of 2022, but the number of these financings more than doubled in Q1 of 2023 – from three to seven – and the amount of money

With investors closely watching how biopharmaceutical companies are spending the cash they have on hand so that they do not run out of money in a tough fundraising environment, even firms with revenue

Rivus Pharmaceuticals Inc. already had its lead Controlled Metabolic Accelerator (CMA), known as HU6, in a Phase IIa clinical trial last year when it raised $35m in series A venture capital. Now, wit